By the end of June, the HUB in collaboration with TaskForceHealthcare will host a workshop in the Hague for life sciences companies that are considering to enter the US healthcare and/or capital market. During the workshop that will take place on July 1st, experts will share tips, tricks and first-hand experience on why, when and how to enter the US market. Stay tuned for the definitive details (time and location).
|
Joris has extensive experience with corporate development, business development and innovation management. Scope ranges from assessing the business feasibility of early concepts to setting the innovation agenda for large bluechip companies. He has led teams of up to 10 members, analyzed over 200 start-ups and scale-ups and has been the business mentor of over 40 start-ups in the USA and the Netherlands. In oncology, Joris has focused on integrated solutions along the cancer care path (e.g. PRO tools, treatment planning, therapy selection, use of AI to improve diagnostic accuracy), the ‘therapy-diagnostics’ convergence and immunotherapies. He also gained experience in cardiology and various chronic diseases. He has experience with consumer health/digital health, medical devices, medical diagnostics and pharma/ biotech. Joris is the founder of &INNOVATE supporting Life Sciences & Health Tech companies with Business Development, Innovation Management and Strategy Consultancy. Joris double-majored in Applied Physics and BioMedical Engineering (Medical Cell BioPhysics) and attended executive education programs at Harvard Business School (Finance for Senior Executives) and Berkeley Haas School of Business (Venture Capital Executive Program). |
Joris Bokkes Senior Director j.bokkes@hollandusbridge.com
|
|
Chris Wilson PhD FRSC has more than 10 years senior leadership experience in the medical device field and 15 years leading R&D in life science, pharma and medical devices. Chris has extensive experience in the development, regulatory approval and commercialization of medical devices. Chris’ passion lies at the interface between advanced materials, electronics and the human body. |
Chris Wilson
|
|
Anula has been investing in life sciences and health care since 2001. She combines successful investment expertise and industry operating experience together with scientific and medical knowledge. Most recently Anula formed EXXclaim Capital to capture the compelling yet under-invested business opportunity in women’s health. |
Anula Jayasuriya
|
|
Charlie has over 20 years of management consulting, business development, and investing experience in more than 40 countries. He is SVP, Strategy, at Cooley LLP, a global law firm that has extensive experience working with life science and tech companies and venture funds. Charlie’s experience ranges from working on strategy with Fortune 500 companies, to counseling emerging technology and life science companies, to venture investing. In addition, he mentors emerging companies and has been a judge for business plan competitions in the US and in Europe. |
Charlie Cameron
|
|
Dr. Gullans has broad experience across the life sciences industry including being a board director at Gemphire since 2016. Previously Dr. Gullans was Managing Director at Excel Venture Management, a Boston-based life sciences venture capital firm which he co-founded in 2008. At Excel, he spearheaded many successful investments in a variety of therapeutics and diagnostics companies, including Cleveland HeartLab. Prior to Excel, Dr. Gullans was co-founder and CEO of RxGen, Inc. and Chief Scientific Officer at U.S. Genomics. |
Steve Gullans
|
|
Cees is co-founder and executive director of the HUB. Together with Jasper he is overall responsible for the HUB program and the Dutch operations. Cees has a background in corporate law with more than a decade of experience in the fields of life sciences, innovation, IP, strategy and execution. Cees is also partner of Whale Bay & Co. Before founding HUB and Whale Bay & Co, Cees worked at Deloitte, and Simmons & Simmons serving a variety of clients. |
Cees de Wit Executive Director +31 6 23 340 588 c.dewit@hollandusbridge.com |
|
Senior Executive with international experience in Biotechnology and Pharma. Management appointments in Large and Mid-Cap US/EU Biopharma companies. Proven track record with product approvals, financing, M&A and IPO. Part of the management Team that Roadshowed ZymoGenetics inc (Nasdaq: ZGEN) through Private Placement, IPO and follow-on offerings. Incorporated ProFibrix Inc in 2008, and as CEO in 2013 led ProFibrix through M&A with The Medicines Company after successful Phase 3 completion and product approvals in EU and US. Board appointments in private and public companies. |
Jan Ohrstrom MD
|
|
Michael Bogenstaetter has over 15 years experience in Biopharma R&D and commercialization of innovative therapies having worked in different leadership roles with companies such as Johnson & Johnson, Novartis and Sanofi and having advised leading Biopharma organizations as member of the Health Care practice of The Boston Consulting Group. |
Michael Bogenstaetter
|
|
Medical Oncology expert with extensive clinical background, strong analytical capabilities, and 20 years in multidisciplinary oncology research & development. Expertise involving biotech drug evaluation, licencing, mergers and acquisitions, mid to late stages clinical development ( NDAs/MAAs; Taxotere, Eloxatin, Xtandi, Onyvide, Oncaspar & Iclusig) and early phases of Immune-Oncology. |
Deyaa Adib
|
|
Babak Movassaghi, PhD, MBA is an entrepreneur and leader working to harness technology to help patients around the world access better healthcare. As Founder and President of InfiniteMD, he draws upon his success in international business development, operational transformation, team building, product innovation, and investments to form strategic business alliances, driving InfiniteMD’s innovation and growth. |
Babak Movassaghi
|
|
Rajiv (Raj) Gupta, MD, PhD is a neuroradiologist and ER radiologist in Boston, MA, an Associate Professor of radiology at Harvard Medical School, and a lecturer in Mechanical Engineering at MIT. He is interested in both research and clinical practice of radiology, currently devoting approximately 50% of his time to each of these activities. |
Raj Gupta
|
|
Rory Carrillo has extensive product development, quality, and regulatory (ISO13485, FDA, CE Mark) experience, and has developed and successfully led the regulatory clearance for many Class II and Class III products, both hardware and software. He has experience with developing and receiving clearance for digital health, wearable, and AI-based products including algorithms used for detection and diagnosis. |
Rory Carrillo
|
|
I am a savvy strategist & business developer with 20 years of experience in the Life Sciences. Currently, I am the CBO of TRACER Europe and North America, and the CEO of AxelaRx Biosciences Inc. |
Ari Aminetzah
|
|
Renata is a highly successful Global Pharmaceutical Project and Functional Leader with 30+ years extensive experience in the scientific and clinical development, regulatory approval and commercialisation of new medicines. Renata started her career in academic research at St Thomas’s Hospital, London working on cardiovascular research and heart transplantation. |
Renata Crome
|
